Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Methocarbamol + aspirin** is an oral combination drug used to treat pain and muscle spasm associated with musculoskeletal disorders. **Aspirin** (a salicylate) acts as an analgesic and anti-inflammatory by irreversibly inhibiting cyclooxygenase (COX), thus reducing the production of prostaglandins involved in pain and inflammation. **Methocarbamol** is a centrally acting muscle relaxant; its mechanism is not fully established but is believed to involve general depression of the central nervous system leading to decreased muscle spasms. The combination is typically used alongside rest and physical therapy for short-term management of musculoskeletal conditions[1][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methocarbamol + aspirin.